Filali Bouami Soufiane, Gwiasda Jill, Beneke Jan, Kaltenborn Alexander, Liersch Sebastian, Suero Eduardo M, Koch Hans-Friedrich, Krauth Christian, Klempnauer Jürgen, Schrem Harald
Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
Langenbecks Arch Surg. 2018 Jun;403(4):495-508. doi: 10.1007/s00423-018-1670-5. Epub 2018 Apr 2.
Prognostic factors for survival ≥ 15 years and life years lost after liver transplantation are largely unknown.
One thousand six hundred thirty primary adult liver transplants between 1983 and 2014 were analyzed. Risk factors for survival were identified with multivariable Cox regression and subsequently tested for their relevance as prognostic factors for observed 15-year survival using multivariable logistic regression and c statistics. The difference of life expectancy between a matched national reference population and survival in patients with post-transplant survival ≥ 15 years was calculated.
Survival of ≥ 15 years was observed in 361 patients (22%). Sixty-nine adults died after more than 15 years losing a median of 15 years of life expectancy. One of those patients lived longer while 292 patients still have the chance to survive longer than their normal life expectancy. The indication primary sclerosing cholangitis (PSC) and later eras of transplantation were identified as significant independent protective factors while recipient age > 36.8 years, graft loss due to initial non-function or thrombosis, the indications hepatocellular carcinoma (HCC), hepatitis-C-virus-related cirrhosis (HCV-cirrhosis) and all other indications, donor age > 53 years, the number of surgical complications, and operative durations > 4.5 h were identified as significant independent risk factors limiting survival. All of these factors except the duration of operation had also a significant independent influence on observed 15-year survival (AUROC = 0.739).
Recipients can exceptionally live longer than their normal life expectancy. Older recipients and patients with the indications HCC, HCV-cirrhosis, or other indications except PSC, should be transplanted with younger donor organs.
肝移植术后生存≥15年及寿命损失的预后因素大多未知。
分析了1983年至2014年间的1630例成人原发性肝移植。通过多变量Cox回归确定生存的危险因素,随后使用多变量逻辑回归和c统计量检验其作为观察到的15年生存率预后因素的相关性。计算匹配的全国参考人群与移植后生存≥15年患者的预期寿命差异。
361例患者(22%)生存≥15年。69例成年人在超过15年后死亡,平均损失15年预期寿命。其中1例患者存活时间更长,而292例患者仍有机会存活超过其正常预期寿命。原发性硬化性胆管炎(PSC)这一适应证以及移植的后期时代被确定为显著的独立保护因素,而受者年龄>36.8岁、因初始无功能或血栓形成导致的移植物丢失、肝细胞癌(HCC)、丙型肝炎病毒相关肝硬化(HCV肝硬化)及所有其他适应证、供者年龄>53岁、手术并发症数量以及手术持续时间>4.5小时被确定为限制生存的显著独立危险因素。除手术持续时间外,所有这些因素对观察到的15年生存率也有显著的独立影响(曲线下面积=0.739)。
受者有可能异常地活得比其正常预期寿命更长。年龄较大的受者以及患有HCC、HCV肝硬化或除PSC外其他适应证的患者,应使用较年轻供者的器官进行移植。